Patents Issued in February 14, 2017
-
Patent number: 9566291Abstract: The present invention provides a method and composition for the treatment and/or prevention of respiratory tract infection and/or respiratory tract infection disease, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and at least 5 wt. % digestible galactose saccharide.Type: GrantFiled: August 24, 2005Date of Patent: February 14, 2017Assignee: N.V. NutriciaInventors: Günther Boehm, Laura M'Rabet, Bernd Stahl, Johan Garssen
-
Patent number: 9566292Abstract: This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided.Type: GrantFiled: June 8, 2015Date of Patent: February 14, 2017Assignee: Creation One Formulators, LLCInventors: Lee A. Bulla, Jr., Jeffrey Marcus Clark, Natalya Griko, Jian Sun
-
Patent number: 9566293Abstract: The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.Type: GrantFiled: October 19, 2015Date of Patent: February 14, 2017Assignee: Roche Innovation Center Copenhagen A/SInventors: Gregroy Hardee, Ellen Marie Straarup, Marie Wickstrom Lindholm, Henrik Orum, Henrik Frydenlund Hansen
-
Patent number: 9566294Abstract: The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicants' surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.Type: GrantFiled: April 2, 2013Date of Patent: February 14, 2017Assignee: Northwest Biotherapeutics, Inc.Inventors: Gerald P. Murphy, Alton L. Boynton, Anil Sehgal
-
Patent number: 9566295Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.Type: GrantFiled: October 6, 2014Date of Patent: February 14, 2017Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
-
Patent number: 9566296Abstract: Compositions and methods are provided for preparing an adhesion barrier in the form of a foldable or flexible biodegradable polymer matrix that effectively reduces, prevents or treats adhesions in a patient in need thereof. In one embodiment, the matrix comprises a first porous layer comprising collagen and a second porous layer comprising collagen and dextran, wherein the dextran is loaded in the second layer in an amount of from about 5% to about 90% by weight based on a total weight of the matrix. In some embodiments, the matrix prevents or reduces cell growth into the matrix so as to reduce or prevent adhesions. In some embodiments, the matrix is in a sheet or strip form that can be folded into a tube form.Type: GrantFiled: November 8, 2013Date of Patent: February 14, 2017Assignee: Warsaw Orthopedic, Inc.Inventor: Scott M. Vickers
-
Patent number: 9566297Abstract: The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to Tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery. This application is a continuation in part to U.S. patent application Ser. No. 13/202,006. The novel biocompatible conjugate compound of the original application can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that the conjugate compound effectively inhibits the invasion of cells which is associated with detrimental healing processes without affecting platelet populations. Use of any of several different anionic components with any of several different anti-platelet agents results in many different specific embodiments of the invention.Type: GrantFiled: March 24, 2014Date of Patent: February 14, 2017Assignee: Novelmed Therapeutics, Inc.Inventor: Rekha Bansal
-
Patent number: 9566298Abstract: The present invention provides methods for treating acute kidney injury through introduction of one or more drag reducing polymers, oligomers, and/or monomers, as well as compositions that include therapeutic amounts of one or more of these drag reducing polymers, oligomers, and/or monomers. These compositions may also include additional components that enhance at least one of the stability, effectiveness, or administerability of the polymers, oligomers, and/or monomers—such as buffers, anti-oxidants, and enzyme inhibitors.Type: GrantFiled: June 30, 2015Date of Patent: February 14, 2017Assignee: HemaFlo Therapeutics Inc.Inventor: Dale R. Peterson
-
Patent number: 9566299Abstract: The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof comprising mixture of water and organic solvent(s) and/or less than of about 10% of plasticizing agent in the coating composition. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises mixture of water and organic solvent(s) and less than of about 10% of plasticizing agent in coating. The invention also includes process of preparing such composition.Type: GrantFiled: February 5, 2014Date of Patent: February 14, 2017Assignee: WOCKHARDT LIMITEDInventors: Girish Kumar Jain, Venkataramana Naidu, Abdul Rehman Khan, Amar Agarwal, Srikanth Pattipati
-
Patent number: 9566300Abstract: The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.Type: GrantFiled: December 4, 2015Date of Patent: February 14, 2017Inventor: William A. Shaver
-
Patent number: 9566301Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%), or more specifically between about 0.015% to about 5%, sodium iodine or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.Type: GrantFiled: March 28, 2013Date of Patent: February 14, 2017Assignee: CXL OPHTHALMICS, LLCInventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
-
Patent number: 9566302Abstract: The present invention provides a composition comprising (i) a mixed metal compound containing at least one trivalent metal selected from iron (lll) and aluminum and at least one divalent metal selected from of magnesium, iron, zinc, calcium, lanthanum and cerium, (ii) xanthan gum (iii) at least one of (a) polyvinyl pyrrolidone (b) locust bean gum (c) methyl cellulose wherein the composition has been irradiated with ionizing radiation in an amount of at least 4 kGy.Type: GrantFiled: February 3, 2011Date of Patent: February 14, 2017Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Richard Jonathan Applewhite, Alexis John Toft
-
Patent number: 9566303Abstract: Compositions comprising ferrous and/or ferric iron compounds and fiber in a complex, methods for preparing such compositions of matter, and the use thereof for treatment of adsorbing certain accessible targets in the gastrointestinal tract and in an extracorporeal system, are provided herein.Type: GrantFiled: October 12, 2012Date of Patent: February 14, 2017Assignee: Vidasym, Inc.Inventor: Jinshyun Ruth Wu-Wong
-
Patent number: 9566304Abstract: Provided is a pharmaceutical composition for preventing or treating cancer, and more particularly, a pharmaceutical composition for preventing or treating cancer, including dendritic cells with a knock-down Dab2 gene. The composition includes a dendritic cell in which a Dab2 gene is knocked down or knocked out or activity of a Dab2 protein is suppressed as an active ingredient, and thus is expected to be useful as a pharmaceutical composition to prevent, improve or treat cancer as a result of having improved antigen uptake, a migration ability of a cell to a lymph node, and expression of inflammatory cytokines, and activating antigen-specific cytotoxic T cell lymphocyte (CTL) and related T cells that can attack cancer cells, and therefore is expected to be used as the pharmaceutical composition for preventing, improving or treating cancer.Type: GrantFiled: November 7, 2014Date of Patent: February 14, 2017Assignee: Research & Business Foundation Sungkyunkwan UniversityInventors: Yong-Soo Bae, Se Eun Byeon, Selim Ahmed, Yideul Jeong
-
Patent number: 9566305Abstract: Therapeutic compositions for addressing physiological stresses and aging include an immune modulator and one or more adaptogenic nutrients. Some non-limiting examples of immune modulators include as transfer factor, low molecular weight fraction immune modulators and/or other low molecular weight fractions of colostrum, egg or any other source of transfer factor or low molecular weight fraction immune modulators. Methods for administering immune modulators and adaptogenic nutrients to a subject to address the effects of physiological stresses and aging in the body of the subject, such as inflammatory responses, are also disclosed.Type: GrantFiled: October 13, 2014Date of Patent: February 14, 2017Assignee: 4LIFE PATENTS, LLCInventor: Christopher M. Lockwood
-
Patent number: 9566306Abstract: The disclosure of the present application includes topically administrable compositions and methods for treating wounds and inflammatory conditions of the skin in mammals. In an exemplary embodiment, the composition includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more of these; a therapeutic amount of creatine; a therapeutic amount of creatinine; and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination of these. The combination of non-sedating antihistamine, creatine, and creatinine with emu oil has been found to produce a synergistic effect that is more effective in the treatment of skin wounds than the compounds used separately.Type: GrantFiled: March 17, 2013Date of Patent: February 14, 2017Assignee: Zemtsov Enterprises, LLCInventor: Alexander Zemtsov
-
Patent number: 9566307Abstract: A pharmaceutical composition contains a coxsackievirus A11 type that infects cancer cells or an echovirus 4 type that infects cancer cells. The coxsackievirus A11 type and the echovirus 4 type may have capsid eliminated. The pharmaceutical composition has an intensive cytotoxicity to a cell of cancer selected from the group consisting of small cell lung cancer, non-small cell lung cancer, lung squamous cell carcinoma, malignant mesothelioma, colorectal cancer, colon/rectum cancer, esophageal cancer, hypopharynx cancer, human-B-lymphocyte tumor, breast cancer, cervical cancer, and pancreatic cancer, which is the cancer cells of a solid cancer.Type: GrantFiled: April 19, 2013Date of Patent: February 14, 2017Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Kenzaburo Tani, Hiroyuki Inoue, Keisuke Yasunari, Shohei Miyamoto
-
Patent number: 9566308Abstract: A medicinal preparation, a process, a nutritional composition and regenerative and insulin potentiating method for humans and also for mammals for prevention, treatment and management/glycemic control, of diabetes mellitus by obtaining optimum glucose level in blood, by administering an extract of Costus pictus to produce above effect in a dose of 500-200 mg/day in humans and 50-200 mg/kg/day in rats. A method for treating hyperglycemia in a patient by administering a medicinal preparation of Costus pictus D. Don. A method for long term management of diabetes by avoiding the problems associated with tight control of blood glucose concentrations, i.e., hypoglycemia tolerance and seizures, while simultaneously avoiding the problems associated with conventional moderate control of blood glucose concentrations, i.e., pathological complications associated with hyperglycemia, such as nephropathy, retinopathy, etc.Type: GrantFiled: January 16, 2014Date of Patent: February 14, 2017Inventor: Merina Benny Antony
-
Patent number: 9566309Abstract: Disclosed are compositions containing extracts of (a) Panax ginseng C. A. Mayer, (b) Zingiber officinale, (c) Echinacea angustifolia and (d) Silybum marianum or the phospholipid complex of silybin with phospholipids as active ingredients, mixed with suitable excipients.Type: GrantFiled: July 11, 2013Date of Patent: February 14, 2017Assignee: INDENA S.P.A.Inventors: Ezio Bombardelli, Fabrizio Corti
-
Patent number: 9566310Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.Type: GrantFiled: March 15, 2013Date of Patent: February 14, 2017Assignee: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENOInventors: Dean Burkin, Ryan Wuebbles
-
Patent number: 9566311Abstract: The present invention relates to pharmaceutical compositions having improved stability.Type: GrantFiled: September 29, 2011Date of Patent: February 14, 2017Assignee: Ferring B.V.Inventors: Britta Siekmann, Mattias Malm, Anders Nilsson, Kazimierz Wisniewski
-
Patent number: 9566312Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, and A-B are as defined herein, which are non-immunosuppressive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.Type: GrantFiled: May 20, 2015Date of Patent: February 14, 2017Assignee: Novartis AGInventors: Jiping Fu, Subramanian Karur, Xiaolin Li, Peichao Lu, Wosenu Mergo, Alexey Rivkin, Zachary Kevin Sweeney, Meiliana Tjandra, Andrew Weiss, Aregahegn Yifru
-
Patent number: 9566313Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.Type: GrantFiled: June 1, 2010Date of Patent: February 14, 2017Assignees: MERCK SERONO SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Yolande Chvatchko, Alain Tedgui, Ziad Mallat
-
Patent number: 9566314Abstract: The present invention provides compositions and methods for providing factor replacement therapy. In particular, the present invention provides replacement therapy for subjects suffering from cystinosis.Type: GrantFiled: April 21, 2015Date of Patent: February 14, 2017Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jess Thoene, Jeffrey Innis
-
Patent number: 9566315Abstract: Methods of normalizing bile acid production in a mouse engrafted with human hepatocytes by the administration of human FGF19 are disclosed. Also disclosed is a transgenic host animal, such as a mouse, that expresses human FGF19 that has normalized bile acid production when engrafted with human hepatocytes.Type: GrantFiled: October 30, 2014Date of Patent: February 14, 2017Assignee: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Markus Grompe, Willscott Naugler
-
Patent number: 9566316Abstract: Described herein are variant, recombinant ?-glucocerebrosidase proteins characterized as having increased stability relative to recombinant wild-type ?-glucocerebrosidase. Also provided herein are variant, recombinant ?-glucocerebrosidase proteins characterized as retaining more catalytic activity relative to recombinant wild-type ?-glucocerebrosidase. Further described herein are variant, recombinant ?-glucocerebrosidase proteins that can have amino acid variations at one or more of the following positions: 316, 317, 321 and 145. Methods of making the variant, recombinant ?-glucocerebrosidase proteins are also described as well as methods of treating patients having lysosomal storage diseases.Type: GrantFiled: January 4, 2016Date of Patent: February 14, 2017Assignee: AMICUS THERAPEUTICS, INC.Inventor: Hung V. Do
-
Patent number: 9566317Abstract: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met.Type: GrantFiled: January 22, 2016Date of Patent: February 14, 2017Assignee: Osio CorporationInventor: Alberto Osio Sancho
-
Patent number: 9566318Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimizing the progression of cancer in said individuals.Type: GrantFiled: July 2, 2012Date of Patent: February 14, 2017Assignee: Biosceptre (Aust) Pty LtdInventors: Julian Alexander Barden, Angus Gidley-Baird
-
Patent number: 9566319Abstract: Described are particular fragments of the cyclin-dependent kinase inhibitor p16 capable of increasing IFN-? secretion of T cells or inducing proliferation of T cells and the use of said fragments for immunizing an individual against HPV-associated or other p16INK4a expressing carcinomas, preferably advanced carcinomas.Type: GrantFiled: July 15, 2015Date of Patent: February 14, 2017Assignee: Ruprecht-Karls-Universitaet HeidelbergInventors: Matthias Kloor, Miriam Reuschenbach, Magnus Von Knebel-Doeberitz
-
Patent number: 9566320Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.Type: GrantFiled: September 24, 2014Date of Patent: February 14, 2017Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida
-
Patent number: 9566321Abstract: The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells.Type: GrantFiled: February 16, 2016Date of Patent: February 14, 2017Assignee: VAXIION THERAPEUTICS, LLCInventor: Matthew J. Giacalone
-
Patent number: 9566322Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.Type: GrantFiled: October 14, 2014Date of Patent: February 14, 2017Assignee: SOCPRA—SCIENCES ET GÉNIE, S.E.C.Inventors: François Malouin, Marianne Allard, Christian Lebeau Jacob, Brian Geoffrey Talbot, Daniel Scholl, Pierre Lacasse, Moussa S. Diarra, Céline Ster
-
Patent number: 9566323Abstract: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.Type: GrantFiled: October 20, 2009Date of Patent: February 14, 2017Assignee: Eyegene Inc.Inventors: Hong-Jin Kim, Na Gyong Lee, Yang-Je Cho, Jin-Wook Jang, Hyoung Jin Kim, Kwang Sung Kim
-
Patent number: 9566324Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.Type: GrantFiled: November 9, 2011Date of Patent: February 14, 2017Assignee: Zoetis Services LLCInventors: Jay Gregory Calvert, David Ewell Slade, Siao-Kun W. Welch
-
Patent number: 9566325Abstract: The invention provides methods and kits for inducing a therapeutic immunity in animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. In particular, the invention provides a method of treating animals with an established HSV-2 infection by administering a therapeutic vaccine comprising a priming dose of a nucleic acid encoding an HSV-2 antigen, an initial or first boosting dose comprising the protein form of the antigen encapsulated in liposomes, and one or more subsequent boosting doses comprising both the nucleic acid encoding the HSV-2 antigen and the liposomal-encapsulated protein antigen.Type: GrantFiled: January 7, 2014Date of Patent: February 14, 2017Assignee: BIOMEDICAL RESEARCH MODELS, INC.Inventors: Kejian Yang, Dennis L. Guberski
-
Patent number: 9566326Abstract: An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.Type: GrantFiled: June 21, 2013Date of Patent: February 14, 2017Assignee: Seqirus UK LimitedInventors: Audino Podda, Nicola Groth, Michele Pellegrini
-
Patent number: 9566327Abstract: Described herein is the generation of optimized H5N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.Type: GrantFiled: February 8, 2013Date of Patent: February 14, 2017Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Ted M. Ross, Corey J. Crevar, Brendan M. Giles
-
Patent number: 9566328Abstract: Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2012. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.Type: GrantFiled: February 24, 2016Date of Patent: February 14, 2017Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Ted M. Ross, Corey J. Crevar, Donald M. Carter, Jr.
-
Patent number: 9566329Abstract: Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (ORF) without an in-frame deletion, a rubella structural protein ORF, and a heterologous antigenic insert. In one example, the heterologous antigenic insert is positioned within the rubella structural protein ORF. In some examples, the heterologous antigenic insert is positioned in the rubella structural protein ORF in between a gene encoding structural protein E2 and a gene encoding structural protein E1. Exemplary antigenic inserts include HIV, SIV, RSV or hepatitis B surface antigens. In some examples, the HIV antigenic insert is a Gag antigenic insert, a gp41 antigenic insert or a gp120 antigenic insert. Also disclosed are uses of the isolated rubella viral vector, such as to induce an immune response to a particular virus, such as HIV-1, testing sensitivity to neutralizing antibodies, or screening antiviral drugs (such as protease inhibitors).Type: GrantFiled: April 8, 2013Date of Patent: February 14, 2017Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Ira Berkower, Konstantin Virnik
-
Patent number: 9566330Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.Type: GrantFiled: March 19, 2012Date of Patent: February 14, 2017Inventor: Alexandre Eduardo Nowill
-
Patent number: 9566331Abstract: A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-?, and IFN-?, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.Type: GrantFiled: February 20, 2013Date of Patent: February 14, 2017Assignee: IRX Therapeutics, Inc.Inventors: John W. Hadden, Kathy L. Signorelli, James E. Egan, Paul H. Naylor
-
Patent number: 9566332Abstract: The preset invention relates to combination pharmaceutical composition comprising an activated-potentiated from of an antibody to gamma interferon, and an activated-potentiated form of an antibody to S-100 protein and method of treating multiple sclerosis and other neurodegenerative diseases, as well as the diseases and conditions associated with neuroinfections.Type: GrantFiled: October 8, 2013Date of Patent: February 14, 2017Assignee: Oleg Iliich EpshteinInventor: Oleg Iliich Epshtein
-
Patent number: 9566333Abstract: An isolated DNA molecule comprising a fragment of the gene encoding the feline NIS is disclosed as well as methods of use thereof. Also provided are methods for rational diet design of food composition suitable for administration to feline companion animals afflicted with hyperthyroidism, comprising (a) accessing at least one database that comprises a first data set relating functional gene profile of a biofluid or tissue sample from an animal to physiological condition of the animal, where the functional gene profile is that of the feline NIS gene; (b) accessing at least one database that comprises a second data set relating effects of bioactive dietary components on the functional gene profile; (c) using an algorithm drawing on these data sets, processing input data defining physiological condition to derive a nutritional formula promoting wellness of a feline companion animal afflicted with hyperthyroidism; and (d) preparing a food composition based on the nutritional formula.Type: GrantFiled: December 6, 2012Date of Patent: February 14, 2017Assignee: Hill's Pet Nutrition, Inc.Inventors: Samer Al-Murrani, Jeffrey Brockman
-
Patent number: 9566334Abstract: The invention provides combinations comprising GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof and ME-HD7945A. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer (e.g., triple negative breast cancer).Type: GrantFiled: December 9, 2013Date of Patent: February 14, 2017Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Jose Baselga, Maurizio Scaltriti
-
Patent number: 9566335Abstract: The invention describes methods and reagents useful for sequencing polypeptide molecules. The method comprises affixing a polypeptide to a substrate and contacting the polypeptide with a plurality of probes. Each probe selectively binds to an N-terminal amino acid or an N-terminal amino acid derivative. Probes bound to the polypeptide molecule are then identified before cleaving the N-terminal amino acid or N-terminal amino acid derivative of the polypeptide. Also provided are methods for the sequencing a plurality of polypeptide molecules in a sample and probes specific for N-terminal amino acids or N-terminal amino acid derivatives.Type: GrantFiled: September 27, 2010Date of Patent: February 14, 2017Assignee: The Governing Council of the University of TorontoInventors: Andrew Emili, Megan McLaughlin, Kyrylo Zagorovsky, Jonathan Buchanan Olsen, Warren C. W. Chan, Sachdev S. Sidhu
-
Patent number: 9566336Abstract: The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.Type: GrantFiled: July 28, 2014Date of Patent: February 14, 2017Assignee: pSivida US, Inc.Inventors: Dongling Su, Paul Ashton, Jianbing Chen
-
Patent number: 9566337Abstract: The present invention provides a pharmaceutical formulation prepared as dry syrups representing mere powder mixtures of beta-lactam antibiotics as active pharmaceutical ingredients and excipients without applying any other process steps than simple mixing of dry powder, whereby the pharmaceutical formulation combines two essential properties for processability and dosability: good flowability and high stability against segregation.Type: GrantFiled: July 8, 2014Date of Patent: February 14, 2017Assignee: SANDOZ AGInventors: Stefan Scheler, Johannes Raneburger, Franz Xaver Schwarz, Florian Kern
-
Patent number: 9566338Abstract: The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.Type: GrantFiled: March 11, 2013Date of Patent: February 14, 2017Assignee: University of Georgia Research Foundation, Inc.Inventors: Donald A. Harn, Rafaella Queiroz, Lisa McEwen
-
Patent number: 9566339Abstract: Methods, devices and systems are disclosed for chemically bonding antibiotics to selected substrate materials which are not dissolved in normal physiological processes so that high local concentrations can be achieved during the inflammatory response. The antibiotics will remain permanently bonded to the substrate material until an infection occurs which releases the antibiotic in high concentrations to help control the infection. The high local concentrations may be much higher than systemic toxic levels, and can never reach toxic levels because the local dose is much less than needed to reach systemic toxicity if completely dissolved.Type: GrantFiled: March 14, 2014Date of Patent: February 14, 2017Assignee: Osteoceramics, Inc.Inventor: Thomas D. McGee
-
Patent number: 9566340Abstract: The invention features compounds of formula V or XII: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.Type: GrantFiled: October 20, 2015Date of Patent: February 14, 2017Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Jayaprakash K. Nair, Kallanthottahil G. Rajeev, Michael E. Jung